Restoring Hope for Late Stage Cancer Patients with No Remaining Treatment Options.
Until Now.
Our Immunosync Technology enhances the benefits of conventional cancer care by synchronizing the delivery of treatment with a patient's unique immune status.
Our Technology
Biomarker Analysis
Our proprietary algorithm evaluates immune markers to map the immune system and identify key characteristics of immune readiness.
Tailored Insights
Immunosync adjusts to the specific mode of therapy to be used in the patient treatment plan.
Advanced Analytics
Immunosync identifies the individual characteristics of a patient's immune system to identify the optimal treatment time.
Seamless Integration
Immunosync communicates directly with oncology care providers that adminster therapy based on a patient's unique immune profile,
Optimal Timing
Treatment synchronized with each patient's individual immune status
Personalised Care
Tailored care to each person's immune profile and treatment plan
Enhanced Outcomes
Delivering measurably superior results
Restored Hope
New treatment options for late-stage patients
Clinical Study Results
73%
Local Control using ImmunoSync (4 x Improvement)
Compared to 18% without use.
54%
Survival using ImmunoSync
Palliative patients alive at 2 years.
p=.038
Effect on Survival Rate using ImmunoSync
Effect of survival rates.
55%
Abscopal Effect using Immunosync
compared with 27% without use.
These results demonstrate ImmunoSync’s impact on clinical outcomes—improving local control, extending survival, and enhancing immune-mediated effects across late-stage cancer patients. Backed by peer-reviewed data and measurable improvements, ImmunoSync is redefining treatment timing to deliver tangible benefits in real-world settings.
Scientific Publications
Our research on precision immune mapping has been featured in top-tier medical journals, validating our technology's effectiveness in revolutionizing cancer care approaches.
Novel time-synchronized immune-guided partial tumor irradiation: Proof
of principle trial. (Oct 2024)
of principle trial. (Oct 2024)
"Immunosync provides valuable insights into the critical role of immune cycle synchonization in optimzing radiotherapy outcomes."
Faster, Less Toxic, and More Effective: A Holy Trinity in Palliative Radiotherapy
Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320) (Oct 2024)
Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320) (Oct 2024)
"All measured outcomes were significantly influenced by treatment with ImmunoSync"
Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment (Dec 2019)
"Precision mapping technology identifies novel biomarkers for personalized immunotherapy targeting."
Our Leadership Team
Aldo Rolfo
Commercial Strategy & Patient Access
Dr David Speakman
Chief Medical Officer
Shane Ryan
Strategic Partnerships
Martin Ashdown
Chief Scientific Officer
Daniel Trenton
Managing Director
Dr Slavisa Tubin
Scientific Advisory Board
Dr Sid Baxi
Innovation Lead
Luke Ashdown
IP and Regulatory Lead
Lev Shevki
Commercial Strategy & Gov
Contact Us
Email
dtrenton@lifecycletech.com.au
For general inquiries and information requests.
Phone
(+61) 422096978
Available Monday-Friday, 9am-5pm AEST.
Headquarters
Level 3, 179 Queen Street, Melbourne, Victoria 3000.
Partnerships
Connect with our team for collaboration opportunities.
ImmunoSync is a technology of Lifecycle Oncology pty ltd.